RALLYBIO CORPORATION Marketable Securities, Unrealized Gain (Loss)
RALLYBIO CORPORATION (RLYB) reported Marketable Securities, Unrealized Gain (Loss) of -$1.00 thousand for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-26
- RALLYBIO CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$1.00K.
- RALLYBIO CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$17.00K.
- RALLYBIO CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was -$6.00K.
- RALLYBIO CORPORATION marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $7.00K, a 97.08% decline year-over-year.
- RALLYBIO CORPORATION marketable securities, unrealized gain (loss) for fiscal 2023 was $229.00K.
- RALLYBIO CORPORATION marketable securities, unrealized gain (loss) for fiscal 2022 was -$214.00K.
- RALLYBIO CORPORATION marketable securities, unrealized gain (loss) for fiscal 2021 was $0.00.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K S-4/A · filed 2026-08-26 | -$18.00K S-4/A · filed 2026-08-26 | -$24.00K derived: sum of 3 quarters · filed 2026-08-26 | -$17.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | -$17.00K S-4 · filed 2026-07-15 | -$23.00K derived: sum of 2 quarters · filed 2026-08-26 | -$16.00K derived: sum of 3 quarters · filed 2026-08-26 | -$46.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | -$6.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $1.00K derived: sum of 2 quarters · filed 2026-08-26 | -$29.00K derived: sum of 3 quarters · filed 2026-08-26 | -$50.00K S-4/A · filed 2026-08-26 |
| 2025-09-30 | $7.00K 10-Q · filed 2025-11-06 | -$23.00K derived: sum of 2 quarters · filed 2026-08-26 | -$44.00K 10-Q · filed 2025-11-06 | -$145.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | -$30.00K S-4/A · filed 2026-08-26 | -$51.00K S-4/A · filed 2026-08-26 | -$152.00K derived: sum of 3 quarters · filed 2026-08-26 | $88.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | -$21.00K S-4 · filed 2026-07-15 | -$122.00K derived: sum of 2 quarters · filed 2026-08-26 | $118.00K derived: sum of 3 quarters · filed 2026-08-26 | $118.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | -$101.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $139.00K derived: sum of 2 quarters · filed 2026-08-26 | $139.00K derived: sum of 3 quarters · filed 2026-08-26 | $53.00K S-4/A · filed 2026-08-26 |
| 2024-09-30 | $240.00K 10-Q · filed 2025-11-06 | $240.00K derived: sum of 2 quarters · filed 2025-11-06 | $154.00K 10-Q · filed 2025-11-06 | $377.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | -$86.00K 10-Q · filed 2025-08-07 | $137.00K derived: sum of 3 quarters · filed 2025-08-07 | $201.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$86.00K 10-Q · filed 2025-05-08 | $137.00K derived: sum of 2 quarters · filed 2025-05-08 | $201.00K derived: sum of 3 quarters · filed 2025-05-08 | -$10.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $287.00K derived: sum of 2 quarters · filed 2025-03-13 | $76.00K derived: sum of 3 quarters · filed 2025-03-13 | $229.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $64.00K 10-Q · filed 2024-11-07 | -$147.00K derived: sum of 2 quarters · filed 2024-11-07 | $6.00K 10-Q · filed 2024-11-07 | $226.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$211.00K 10-Q · filed 2024-08-08 | -$58.00K 10-Q · filed 2024-08-08 | $162.00K derived: sum of 3 quarters · filed 2024-08-08 | $99.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $153.00K 10-Q · filed 2024-05-09 | $373.00K derived: sum of 2 quarters · filed 2024-05-09 | $310.00K derived: sum of 3 quarters · filed 2024-05-09 | $61.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $157.00K derived: sum of 2 quarters · filed 2024-03-12 | -$92.00K derived: sum of 3 quarters · filed 2024-03-12 | -$214.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | -$63.00K 10-Q · filed 2023-11-09 | -$312.00K derived: sum of 2 quarters · filed 2023-11-09 | -$434.00K 10-Q · filed 2023-11-09 | -$434.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$249.00K 10-Q · filed 2023-08-08 | -$371.00K 10-Q · filed 2023-08-08 | -$371.00K derived: sum of 3 quarters · filed 2023-08-08 | -$371.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$122.00K 10-Q · filed 2023-05-09 | -$122.00K derived: sum of 2 quarters · filed 2023-05-09 | -$122.00K derived: sum of 3 quarters · filed 2023-05-09 | -$122.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |